TDC
STML

Thompson Davis & Co’s Stemline Therapeutics, Inc. STML Stock Holding History

Thompson Davis & Co’s Portfolio STML Stock Details STML Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		$15K Buy
875
+500
+133% +$8.02K 0.03% 395
2018
Q2 		$6K Hold
375
– – 0.01% 506
2018
Q1 		$6K Buy
+375
New +$5.85K 0.02% 472

Other funds holding STML

CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
PC
Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
LSC
Lyon Street Capital Sausalito, California $67M AUM
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Thompson Davis & Co's STML Position: Q3 2018 in Review

Thompson Davis & Co increased its Stemline Therapeutics, Inc. (STML) stake by 133% in Q3 2018, buying an estimated $8.02K and bringing the position to 875 shares worth $15K. The position accounts for 0.03% of the portfolio, ranked #395.

Thompson Davis & Co first reported a position in STML in Q1 2018 and has held it in 3 quarters since. 90 funds tracked by Wall St. Rank hold STML as of Q3 2018.

  • Thompson Davis & Co held 875 shares of Stemline Therapeutics, Inc. worth $15K as of Q3 2018.
  • Thompson Davis & Co bought 500 Stemline Therapeutics, Inc. shares in Q3 2018, an estimated $8.02K.
  • Stemline Therapeutics, Inc. made up 0.03% of Thompson Davis & Co's portfolio in Q3 2018, its #395 holding.
  • Thompson Davis & Co first reported a position in Stemline Therapeutics, Inc. in Q1 2018 and has held it in 3 quarters since.
  • 90 funds tracked by Wall St. Rank held Stemline Therapeutics, Inc. as of Q3 2018.

Based on Thompson Davis & Co's 13F filing for Q3 2018, filed 14 Nov 2018.